KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Esperion Therapeutics (ESPR) over the last 3 years, with Sep 2024 value amounting to $150,000.

  • Esperion Therapeutics' Capital Expenditures was N/A to $150,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $493,000, marking a year-over-year change of. This contributed to the annual value of $317,000 for FY2024, which is N/A change from last year.
  • Esperion Therapeutics' Capital Expenditures amounted to $150,000 in Q3 2024, which was up 635.71% from -$28,000 recorded in Q2 2024.
  • In the past 5 years, Esperion Therapeutics' Capital Expenditures registered a high of $408,000 during Q1 2020, and its lowest value of -$83,000 during Q3 2020.
  • In the last 1 years, Esperion Therapeutics' Capital Expenditures had a median value of $150,000 in 2024 and averaged $105,667.
  • Data for Esperion Therapeutics' Capital Expenditures shows a peak YoY increase of 115.87% (in 2020) and a maximum YoY decrease of 123.18% (in 2020) over the last 5 years.
  • Over the past 2 years, Esperion Therapeutics' Capital Expenditures (Quarterly) stood at $176,000 in 2020, then followed by $150,000 in 2024.
  • Its Capital Expenditures was $150,000 in Q3 2024, compared to -$28,000 in Q2 2024 and $195,000 in Q1 2024.